Pfizer Switzerland Advances Spend Management Initiatives With Ariba

Ariba, Inc. (Nasdaq:ARBA), the leading spend management solutions provider, today announced that Pfizer Switzerland is expanding its use of Ariba solutions. Pfizer Switzerland has been using a range of Ariba solutions to streamline procurement and lower costs since 2004. To extend and accelerate the savings and efficiencies that it has achieved to date, Pfizer Switzerland is broadening its portfolio beyond procurement to include solutions aimed at enhancing its sourcing process. "A key part of our success in supply management has been the use of Ariba’s spend management solutions, which allow us to drive critical initiatives to manage costs and deliver bottom line results,” said Denise Gerber, Head of Sourcing & Supply Chain Management at Pfizer, Switzerland. An early adopter of spend management solutions, Pfizer Switzerland initially sought to lower its costs of doing business. Leveraging Ariba® Buyer™, the company has achieved this goal by streamlining the procurement of simple and complex categories from orders through invoices and payment. In adding Ariba Sourcing™, Pfizer Switzerland was able to shorten tender processes. Even complex categories of spend such as sales and marketing and professional services can be handled through this module. "Successful sourcing requires more than just technology,” Gerber added. "With Ariba’s deep category expertise and market knowledge, which is a perfect match to our sourcing project teams, we have access to all of the tools we need to advance our initiatives and accelerate the results that they deliver.” "Pfizer Switzerland was among the first companies to embrace spend management and has successfully leveraged technology-based solutions to simplify procurement and lower costs,” said Mike Arenth, Vice President and General Manager, EMEA, Ariba. About Pfizer Schweiz AG Pfizer Schweiz AG is the Swiss subsidiary of Pfizer Inc., the world’s largest research-based pharmaceutical company. The company employs approximately 220 people in Switzerland and sells more than 100 drugs. The main therapeutic classes are cardiovascular disease, diabetes, pulmonary disease, pain, urology, eye disease, nervous disorders, infectiology (including HIV) and oncology. The company also offers a wide range of drugs for livestock and pets. Pfizer has been registered in Switzerland since 1959 and is one of the most important pharmaceutical companies in the country, with sales of more than 300 million CHF, hence Pfizer’s commitment to the base in Switzerland. About Ariba, Inc. Ariba, Inc. is the leading provider of Spend Management solutions to help companies realize rapid and sustainable bottom line results. Successful companies around the world in every industry use Ariba Spend Management™ software and services. Ariba can be contacted in the U.S. at 1.650.390.1000 or at www.ariba.com. Copyright © 1996 – 2008 Ariba, Inc. Ariba, the Ariba logo, AribaLIVE and SupplyWatch are registered trademarks of Ariba, Inc. Ariba Spend Management, Ariba Spend Management. Find it. Get it. Keep it., Ariba. This is Spend Management, Ariba Solutions Delivery, Ariba Analysis, Ariba Buyer, Ariba Category Management, Ariba Category Procurement, Ariba Contract Compliance, Ariba Contracts, Ariba Contract Management, Ariba Contract Workbench, Ariba Data Enrichment, Ariba eForms, Ariba Electronic Invoice Presentment and Payment, Ariba Invoice, Ariba Sourcing, Ariba Spend Visibility, Ariba Travel and Expense, Ariba Procure-to-Pay, Ariba Workforce, Ariba Supplier Network, Ariba Supplier Connectivity, Ariba Supplier Performance Management, Ariba PunchOut, Ariba QuickSource, PO-Flip, Ariba Settlement, Ariba Spend Management Knowledge Base, Ariba Ready, Ariba Supply Lines, Ariba Supply Manager, Ariba LIVE and It’s Time for Spend Management are trademarks or service marks of Ariba, Inc. All other trademarks are property of their respective owners. Ariba Safe Harbor Safe Harbor Statement under the Private Securities Litigation Reform Act 1995: Information and announcements in this release involve Ariba's expectations, beliefs, hopes, plans, intentions or strategies regarding the future and are forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Ariba as of the date of the release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to Ariba's operating and financial results to differ materially from current expectations include, but are not limited to: delays in development or shipment of new versions of Ariba's products and services; lack of market acceptance of Ariba's existing or future products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; the ability to attract and retain qualified employees; difficulties in assimilating acquired companies; long and unpredictable sales cycles and the deferrals of anticipated orders; declining economic conditions; inability to control costs; changes in the company's pricing or compensation policies; significant fluctuations in our stock price; the outcome of and costs associated with pending or potential future regulatory or legal proceedings; the impact of our acquisitions, including the disruption or loss of customer, business partner, supplier or employee relationships; and the level of costs and expenses incurred by Ariba as a result of such transactions. Factors and risks associated with its business, including a number of the factors and risks described above, are discussed in Ariba's Form 10-Q filed with the SEC on February 6, 2008.